1. Home
  2. OR vs NAMS Comparison

OR vs NAMS Comparison

Compare OR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OR
  • NAMS
  • Stock Information
  • Founded
  • OR 2014
  • NAMS 2019
  • Country
  • OR Canada
  • NAMS Netherlands
  • Employees
  • OR N/A
  • NAMS N/A
  • Industry
  • OR Precious Metals
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • OR Basic Materials
  • NAMS Health Care
  • Exchange
  • OR Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • OR 3.5B
  • NAMS 2.7B
  • IPO Year
  • OR N/A
  • NAMS N/A
  • Fundamental
  • Price
  • OR $19.42
  • NAMS $21.12
  • Analyst Decision
  • OR Strong Buy
  • NAMS Strong Buy
  • Analyst Count
  • OR 1
  • NAMS 7
  • Target Price
  • OR $22.00
  • NAMS $41.33
  • AVG Volume (30 Days)
  • OR 551.4K
  • NAMS 651.1K
  • Earning Date
  • OR 02-19-2025
  • NAMS 02-10-2025
  • Dividend Yield
  • OR 0.97%
  • NAMS N/A
  • EPS Growth
  • OR N/A
  • NAMS N/A
  • EPS
  • OR N/A
  • NAMS N/A
  • Revenue
  • OR $183,586,365.00
  • NAMS $33,594,000.00
  • Revenue This Year
  • OR $6.01
  • NAMS $131.53
  • Revenue Next Year
  • OR $27.93
  • NAMS N/A
  • P/E Ratio
  • OR N/A
  • NAMS N/A
  • Revenue Growth
  • OR 1.62
  • NAMS 78.77
  • 52 Week Low
  • OR $12.77
  • NAMS $15.19
  • 52 Week High
  • OR $21.29
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • OR 60.85
  • NAMS 36.68
  • Support Level
  • OR $18.30
  • NAMS $20.40
  • Resistance Level
  • OR $18.93
  • NAMS $23.24
  • Average True Range (ATR)
  • OR 0.51
  • NAMS 1.14
  • MACD
  • OR 0.06
  • NAMS -0.31
  • Stochastic Oscillator
  • OR 88.82
  • NAMS 18.23

About OR Osisko Gold Royalties Ltd

Osisko Gold Royalties Ltd is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. The company organizes and manages the business under two operating segments: (i) acquiring and managing precious metals and other royalties, streams and other interests, and (ii) the exploration, evaluation and development of mining projects. Geographically, it generates majority of the income from North America and also generates some portions of income from South America, Australia, Africa and Europe.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: